News
Macrogen becomes the first company to bring NovaSeq X Plus to Korea, marking its first introduction to the Asian region
○ Macrogen has completed the installation of its first NovaSeq X Plus at its Genome Center in Korea and is gearing up to put in place additional units of the system within this year, which will bring
2023.03.07
Macrogen becomes the first company in Asia to adopt the next generation of genome sequencing technology used to ‘fight diseases’
- Macrogen becomes the world’s first launching partner for Revio, the latest long read sequencing system unveiled on October 27. Revio is expected to increase throughput while lowering costs. - Follow
2023.02.17
Macrogen flings the door open for an era of the $100 genome, as it becomes the first company in the world to adopt the high precision genome sequencer by the U.S.-based Illumina
- Macrogen is the only Korean company among the four companies worldwide serving as a partner for the launch of Illumina’s latest NovaSeq X, unveiled on the 29th. - As the cost of whole-genome sequenc
2023.02.17
Macrogen, K-Quarantine System “Smart Mobile Lab” Export to Indonesia
- First-ever prefab on-site testing system for COVID-19 in Korea - Supply of all-in-one comprehensive mobile container-type COVID-19 testing system - Securing a bridgehead for global export by supplyi
2020.09.28
Macrogen Obtains Europe's CE-IVD Certificate for its COVID-19 Test Kit
- Export of test kit to entire Europe and numerous countries that recognize CE-IVD gains impetus The Korean biotech company Macrogen (CEO Sukang Lee), announced on the 3rd that it had obtained the CE
2020.08.04
Macrogen Approved for Export of its COVID-19 Test Kit
The Korean biotech company Macrogen (CEO Sukang Lee) (KOSDAQ: 038290), announced that it obtained export approval for COVID-19 test kit ‘AxenTM COVID-19 RT’ from the Ministry of Food and Drug Safety (
2020.05.20
The Improved Sperm-freezing Technology Enables Macrogen to Open the Overseas GEM
Now, Get A Free Knock-out Mouse: The Improved Sperm-freezing Technology Enables Macrogen to Open the Overseas GEM Market - Macrogen's improved technology helps to increase Mouse birth rate by 30% - Ma
2020.03.03
Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific
- License and Supply Agreement with Thermo Fisher Scientific signed at Macrogen headquarters - Further development of the global CES market expected by expanding Macrogen’s "Genome Supermarket" strate
2020.01.14
Psomagen-Macrogen Consortium Acquires All Patents & Data from US company uBiome
On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome. Through the move, Psomagen has become a key p in the microbiome sector, a promising n
2020.01.03
Macrogen Research Outcome from ‘Genome Asia 100K’ Covered in Nature
- The largest number of regions and races included in any Asian reference panel - Identification of genome diversity within Asian ethnic groups and differences in drug response SEOUL, South Korea--The
2019.12.05
Macrogen: Successful Construction of the Largest Northeast Asian Reference Panel
- Reference panel expected to contribute to discover the Northeast Asian specific illness-related genes, and to develop tailored diagnosis method - A second reference panel from 10,000 individuals wil
2019.12.04
Psomagen & Macrogen Granted U.S. Patent for Blockchain Data-sharing Technology
- Patent granted for blockchain technology for data transaction brokerage and sharing between data providers and users - Allows individuals to have control over their healthcare data - Technology to b
2019.09.18
Macrogen Announces Strategic Investment in Australian Microbiome Company Microba
- Share subion agreement of 4.1million AUD with Microba - Microbiome data construction in Asia Pacific region within the year, followed by global service launch in early 2020 - Plans to preempt global
2019.06.13
Macrogen Receives GCLP Accreditation
- Macrogen is the first and only NGS-d institute in Korea to receive GCLP accreditation - Increased demands from multinational pharmaceutical companies for NGS analysis for companion diagnostics and t
2019.05.29
Macrogen&Exosome Plus to Jointly Develop Exosome-based Diagnostic and Treatment
- Contract signed for Macrogen to become the exclusive buyer of ‘Exosome Plus’ high-efficiency exosome isolation kit, ‘Exo2D™’ - MOU signed for the joint development of exosome-d diagnostic and treatm
2019.04.24
Macrogen Becomes the First Clinical Lab in Korea to Receive CLIA Accreditation
- NGS labs in Seoul headquarters and Bundang Precision Medicine Center become the first in Korea to receive CLIA accreditation - Only company in Korea with both CLIA and CAP-accredited NGS clinical la
2018.12.27
Macrogen Receives CAP Accreditation in Two Clinical Laboratories in Korea
- NGS Clinical Laboratories in Seoul headquarters and Bundang Precision Medicine Center Simultaneously Received the CAP Accreditation - Expected to Expand the Clinical Diagnostics Market in Korea and
2018.08.13
Establishes Overseas Corporation in Singapore to Focus on Southeast Asian Market
Macrogen Establishes Overseas Corporation in Singapore to Focus on Southeast Asian Market in Earnest - Macrogen establishes ‘Macrogen Asia Pacific’, a Subsidiary in Singapore - Targeting Southeast Asi
2018.06.05
Licenses Gene Editing Technology from Broad Institute of MIT & Harvard in the US
- CRISPR-Cas9 commercial research tool technology acquired from Broad Institute will be used to build preclinical model animals and target treatment function analysis to further gene treatment researc
2018.04.06
Macrogen Corp.'s Clinical NGS Laboratory Receives CAP Accreditation
ROCKVILLE, MD-- Macrogen Corp. (www.macrogenlab.com) announces that its Clinical Lab that provides clinical NGS services has been awarded accreditation by the Accreditation Committee of the College of
2018.04.03
Established its Branch in Spain, Strengthening Localization Service in Europe
Macrogen Established its Branch in Spain, Strengthening Localization Service in Europe - Establishment of Genome Sequencing Industry’s First Branch in Spain, Strengthening Localization Service in Sout
2018.04.02
Leads Precision Medicine by Advancing the Realization of the “$100 Genome Age”
- Completed the Installation of NovaSeq 6000, the Latest Genome Analysis Equipment by Illumina - Capacity for Genome Analysis Service Doubled and Capable of Analyzing More Than 70,000 People Per Year
2018.04.02
Macrogen becomes the first company to bring NovaSeq X Plus to Korea, marking its first introduction to the Asian region
Macrogen becomes the first company in Asia to adopt the next generation of genome sequencing technology used to ‘fight diseases’
Macrogen flings the door open for an era of the $100 genome, as it becomes the first company in the world to adopt the high precision genome sequencer by the U.S.-based Illumina
Macrogen, K-Quarantine System “Smart Mobile Lab” Export to Indonesia
Macrogen Obtains Europe's CE-IVD Certificate for its COVID-19 Test Kit
Macrogen Approved for Export of its COVID-19 Test Kit
The Improved Sperm-freezing Technology Enables Macrogen to Open the Overseas GEM
Macrogen Signs License and Supply Agreement with Thermo Fisher Scientific
Psomagen-Macrogen Consortium Acquires All Patents & Data from US company uBiome
Macrogen Research Outcome from ‘Genome Asia 100K’ Covered in Nature
Macrogen: Successful Construction of the Largest Northeast Asian Reference Panel
Psomagen & Macrogen Granted U.S. Patent for Blockchain Data-sharing Technology
Macrogen Announces Strategic Investment in Australian Microbiome Company Microba
Macrogen Receives GCLP Accreditation
Macrogen&Exosome Plus to Jointly Develop Exosome-based Diagnostic and Treatment
Macrogen Becomes the First Clinical Lab in Korea to Receive CLIA Accreditation
Macrogen Receives CAP Accreditation in Two Clinical Laboratories in Korea
Establishes Overseas Corporation in Singapore to Focus on Southeast Asian Market
Licenses Gene Editing Technology from Broad Institute of MIT & Harvard in the US
Macrogen Corp.'s Clinical NGS Laboratory Receives CAP Accreditation
Established its Branch in Spain, Strengthening Localization Service in Europe
Leads Precision Medicine by Advancing the Realization of the “$100 Genome Age”
TOP